AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36270742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg/day
Number of subjects: 138
Study 36270742 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 138
Study 32776296 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 172
Study 32776296 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing intervention
Number of subjects: 172
Study 32776296 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study 34821437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) target group
Number of subjects: 290
Study 34821437 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 290
Study 32101157 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) bariatric surgery
Number of subjects: 80
Study 33636616 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher seasonally adjusted 25(OH)D levels
Number of subjects: 88
Study 33636616 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25(OH)D levels during spring
Number of subjects: 88
Study 33636616 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonally adjusted 25(OH)D levels below 80 nmol/L
Number of subjects: 88
Study 33636616 — intervention group
Group type: COMPARATOR
Intervention: BMI and cotinine
Number of subjects: 88
Study 33951350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 63
Study 33951350 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 63
Study 32767414 — intervention group
Group type: EXPERIMENTAL
Intervention: Feru-guard 100M (daily for 48 weeks)
Number of subjects: 17
Study 32767414 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 17
Study 36014906 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 10
Study 34501916 — intervention group
Group type: EXPERIMENTAL
Intervention: EC 50%
Number of subjects: 14
Study 34501916 — intervention group
Group type: EXPERIMENTAL
Intervention: EC 100%
Number of subjects: 14
Study 33242020 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (smartphone app and smart band)
Number of subjects: 440
Study 33242020 — intervention group
Group type: COMPARATOR
Intervention: Standard counselling (control group)
Number of subjects: 440
Study 33565409 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (30 minutes, twice daily) on Zusanli, Tianshu, Shangjuxu, Xiajuxu, and Zhongwan, in addition to conventional western medicine for 7 days.
Number of subjects: 100
Study 33565409 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine treatment for 7 days.
Number of subjects: 100
Study 35555246 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2: 0.10)
Number of subjects: 22
Study 35555246 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2: 0.50)
Number of subjects: 22
Study 35555246 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 22
Study 33999414 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment - participants learned of a mood-enhancing treatment and received it
Number of subjects: 125
Study 33999414 — intervention group
Group type: COMPARATOR
Intervention: Treatment deprivation - participants learned of the same treatment, but did not receive it
Number of subjects: 125
Study 33999414 — intervention group
Group type: COMPARATOR
Intervention: Control - treatment was never mentioned
Number of subjects: 125
Study 36540062 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of 400 mg albendazole and either 9‐ or 18 mg ivermectin (single dose or three consecutive days)
Number of subjects: 1097
Study 36540062 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of 400 mg albendazole and either 9‐ or 18 mg ivermectin
Number of subjects: 1097
Study 36540062 — intervention group
Group type: COMPARATOR
Intervention: 400 mg albendazole (control)
Number of subjects: 1097
Study 33545772 — intervention group
Group type: EXPERIMENTAL
Intervention: DPE + PIEB
Number of subjects: 200
Study 33545772 — intervention group
Group type: COMPARATOR
Intervention: CEI + PIEB
Number of subjects: 200
Study 32969884 — intervention group
Group type: EXPERIMENTAL
Intervention: Gunsight procedure
Number of subjects: 143
Study 32969884 — intervention group
Group type: COMPARATOR
Intervention: Purse-string procedure
Number of subjects: 143
Study 33969955 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hyperbaric oxygen (MHO) at 1.3 atmospheres absolute with 31% oxygen for 60 min
Number of subjects: 10
Study 33969955 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) trial for 60 min recovery
Number of subjects: 10
Study 32628582 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic pegaspargase (Hamsyl)
Number of subjects: 29
Study 32628582 — intervention group
Group type: COMPARATOR
Intervention: Reference pegaspargase (Oncaspar)
Number of subjects: 29
Study 32628582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Generic and Reference pegaspargase)
Number of subjects: 29
Study 35705671 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT-BFR
Number of subjects: 20
Study 35705671 — intervention group
Group type: COMPARATOR
Intervention: RIT
Number of subjects: 20
Study 33822134 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and cyclophosphamide followed by weekly paclitaxel (EC-wP)
Number of subjects: 521
Study 33822134 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin and paclitaxel followed by weekly paclitaxel (EP-wP)
Number of subjects: 521
Study 35417857 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscus suturing with ACL plastic surgery
Number of subjects: 66
Study 35417857 — intervention group
Group type: COMPARATOR
Intervention: Meniscus resection with ACL surgery
Number of subjects: 66
Study 32126851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented dual-mobility cup (DMC) replacement
Number of subjects: 62
Study 32126851 — intervention group
Group type: COMPARATOR
Intervention: Cemented 32-mm head total hip replacement (THR)
Number of subjects: 62
Study 32873258 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent short break intervention
Number of subjects: 360
Study 33347874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active food preparation (making a wrap)
Number of subjects: 80
Study 33347874 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive video preparation (watching video of researcher making a wrap)
Number of subjects: 80
Study 33347874 — intervention group
Group type: COMPARATOR
Intervention: Distraction (a non‐food colouring task)
Number of subjects: 80
Study 33347874 — intervention group
Group type: COMPARATOR
Intervention: No time control
Number of subjects: 80
Study 32450917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Plasma-Lyte 148 (Plasmalyte)
Number of subjects: 800
Study 32450917 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 800
Study 34799534 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal infusion of capsaicin
Number of subjects: 26
Study 34799534 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 26
Study 34799534 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin infusion
Number of subjects: 26
Study 34640398 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg (CAF-9)
Number of subjects: 12
Study 34640398 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 12 mg/kg (CAF-12)
Number of subjects: 12
Study 34640398 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 12
Study 34640398 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CAF-9 vs. CAF-12
Number of subjects: 12
Study 34180246 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom minimizers (High KCCQ‐CS and high VE/VCO2 slope)
Number of subjects: 2062
Study 34180246 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom magnifiers (Low KCCQ‐CS and low VE/VCO2 slope)
Number of subjects: 2062
Study 34180246 — intervention group
Group type: COMPARATOR
Intervention: Concordant-lower severity participants (High KCCQ‐CS and low VE/VCO2 slope)
Number of subjects: 2062
Study 35930542 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Assets Supporting Transitions (CAST) intervention
Number of subjects: 0
Study 32293514 — intervention group
Group type: EXPERIMENTAL
Intervention: PROUD intervention for increasing medication treatment of opioid use disorders (OUDs)
Number of subjects: 0
Study 32293514 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses including patients newly diagnosed post-randomization
Number of subjects: 0
Study 35641822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed’s suture modified NPDS
Number of subjects: 103
Study 35641822 — intervention group
Group type: COMPARATOR
Intervention: Conventional NPDS
Number of subjects: 103
Study 34380498 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for mothers of preterm infants
Number of subjects: 80
Study 34380498 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 32298279 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Proneness (AP)
Number of subjects: 0
Study 32298279 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 0
Study 35063963 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (12.5 mg single dose after induction of anaesthesia)
Number of subjects: 230
Study 35063963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose after induction of anaesthesia)
Number of subjects: 230
Study 35063963 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 230
Study 35063963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 33670999 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil supplementation (EVCO)
Number of subjects: 45
Study 33670999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 34726747 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized recommendations
Number of subjects: 104
Study 34726747 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 32931684 — intervention group
Group type: EXPERIMENTAL
Intervention: Information only (IO) group received text messages with HIV prevention information.
Number of subjects: 218
Study 32931684 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus (IP) group received text messages and could win incentives by answering quiz questions and testing for HIV.
Number of subjects: 218
Study 32931684 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (nonrandomized)
Number of subjects: 218
Study 34229315 — intervention group
Group type: EXPERIMENTAL
Intervention: ChRmine
Number of subjects: 0
Study 34229315 — intervention group
Group type: COMPARATOR
Intervention: ChrimsonR
Number of subjects: 0
Study 35762489 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 426
Study 35762489 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 426
Study 33359379 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Band Resistance Training (EBRT)
Number of subjects: 65
Study 33359379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell Resistance Training (DBRT)
Number of subjects: 65
Study 33359379 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 65
Study 32729342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion and chorion allograft (dHACA) plus standard of care (SOC)
Number of subjects: 0
Study 32729342 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 0
Study 34743530 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 months of DAPT after coronary stent procedures
Number of subjects: 568540
Study 34050972 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab (Ven-Obi)
Number of subjects: 0
Study 34050972 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil-obinutuzumab (Clb-Obi)
Number of subjects: 0
Study 35796669 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 32
Study 35796669 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 32
Study 34055704 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching and usual care
Number of subjects: 114
Study 34055704 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 114
Study 35604744 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS‐MPH (osmotic‐release oral system methylphenidate)
Number of subjects: 173
Study 35604744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 33935094 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins (folic acid 0.8 mg, vitamin B12 0.5 mg, vitamin B6 20 mg)
Number of subjects: 196
Study 33935094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 34971816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 160
Study 34971816 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PRO)
Number of subjects: 160
Study 32871328 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 1923
Study 35896694 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1206 (60 mg subcutaneously every 6 months)
Number of subjects: 455
Study 35896694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 34670396 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided therapy
Number of subjects: 0
Study 33006997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IPV prevention intervention)
Number of subjects: 425
Study 33006997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 425
Study 36041669 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263
Study 36041669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 33390325 — intervention group
Group type: EXPERIMENTAL
Intervention: EP0057 (15 mg/m2 Q2W) plus paclitaxel (80 mg/m2, 3 weeks on/1 week off)
Number of subjects: 30
Study 33073501 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (sympathetic nerve fibers in ligamentum flavum)
Number of subjects: 15
Study 33073501 — intervention group
Group type: COMPARATOR
Intervention: Control group (cadaver specimens)
Number of subjects: 15
Study 33073501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic nerve fibers distribution
Number of subjects: 15
Study 33073501 — intervention group
Group type: EXPERIMENTAL
Intervention: 1H-NMR analysis of LF spinal canal
Number of subjects: 15
Study 33073501 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients with vertebral artery dissection
Number of subjects: 15
Study 34984791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 4304
Study 34984791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 33338829 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 1431
Study 33338829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1431
Study 32499064 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG‐ZEBOV‐GP vaccine
Number of subjects: 0
Study 32499064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35770659 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-action observation group
Number of subjects: 60
Study 35770659 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation group
Number of subjects: 60
Study 35770659 — intervention group
Group type: EXPERIMENTAL
Intervention: Action practice group
Number of subjects: 60
Study 35770659 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-action observation group
Number of subjects: 60
Study 35770659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 34030873 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative Low-Dose Dexmedetomidine
Number of subjects: 0
Study 34030873 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33089290 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gargle combined with mechanical debridement
Number of subjects: 100
Study 33089290 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement (Control)
Number of subjects: 100
Study 36197699 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (group A)
Number of subjects: 47
Study 36197699 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clean intermittent catheterization (CIC) within the first postoperative month (group B)
Number of subjects: 47
Study 36197699 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (group A) at 9 months
Number of subjects: 47
Study 36197699 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clean intermittent catheterization (CIC) at 9 months (group B)
Number of subjects: 47
Study 36197699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at 3, 6, and 9 months follow-up
Number of subjects: 47
Study 34997635 — intervention group
Group type: EXPERIMENTAL
Intervention: UNI-PAHNP (Pender's health promotion model‐based Physical Activity and Healthy Nutrition Program)
Number of subjects: 110
Study 32193269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid CBT
Number of subjects: 25
Study 32193269 — intervention group
Group type: COMPARATOR
Intervention: self-help control treatment
Number of subjects: 25
Study 32745170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 3147
Study 32745170 — intervention group
Group type: EXPERIMENTAL
Intervention: E6/E7 mRNA
Number of subjects: 3147
Study 32745170 — intervention group
Group type: EXPERIMENTAL
Intervention: p16/ki67
Number of subjects: 3147
Study 32745170 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate referral
Number of subjects: 3147
Study 32745170 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall referral
Number of subjects: 3147
Study 32745170 — intervention group
Group type: COMPARATOR
Intervention: 1-year retesting vs immediate colposcopy
Number of subjects: 3147
Study 32745170 — intervention group
Group type: EXPERIMENTAL
Intervention: E6/E7 mRNA negative women
Number of subjects: 3147
Study 32745170 — intervention group
Group type: EXPERIMENTAL
Intervention: p16/ki67 negative women
Number of subjects: 3147
Study 32560735 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education program for over 12 months
Number of subjects: 0
Study 32560735 — intervention group
Group type: COMPARATOR
Intervention: General information about the correct use of complex dosage forms (Control)
Number of subjects: 0
Study 32560735 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education program
Number of subjects: 0
Study 36170036 — intervention group
Group type: EXPERIMENTAL
Intervention: TCFA-positive lesions
Number of subjects: 390
Study 36170036 — intervention group
Group type: COMPARATOR
Intervention: TCFA-negative lesions
Number of subjects: 390
Study 33183107 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-based criteria for reduction
Number of subjects: 80
Study 33183107 — intervention group
Group type: COMPARATOR
Intervention: No expert-based criteria for reduction
Number of subjects: 80
Study 34450619 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir 300 mg
Number of subjects: 18
Study 34450619 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir 600 mg
Number of subjects: 18
Study 34450619 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir 800 mg
Number of subjects: 18
Study 34450619 — intervention group
Group type: COMPARATOR
Intervention: Control (standard-of-care)
Number of subjects: 18
Study 32702335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 6 months
Number of subjects: 1500
Study 32702335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 33557706 — intervention group
Group type: EXPERIMENTAL
Intervention: Liars (participants who exaggerated the number of stolen items)
Number of subjects: 0
Study 33557706 — intervention group
Group type: EXPERIMENTAL
Intervention: Liars (participants who fabricated additional stolen items)
Number of subjects: 0
Study 33557706 — intervention group
Group type: COMPARATOR
Intervention: Truth-tellers (participants who reported accurately)
Number of subjects: 0
Study 33557706 — intervention group
Group type: COMPARATOR
Intervention: Believability feedback (believable vs. not believable)
Number of subjects: 0
Study 34979421 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT-CBT
Number of subjects: 50
Study 34979421 — intervention group
Group type: COMPARATOR
Intervention: INFO
Number of subjects: 50
Study 33143327 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest video intervention
Number of subjects: 0
Study 33143327 — intervention group
Group type: COMPARATOR
Intervention: Urban video control
Number of subjects: 0
Study 34746976 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-assisted internet-delivered cognitive behaviour therapy program
Number of subjects: 13
Study 32838628 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 9
Study 32838628 — intervention group
Group type: EXPERIMENTAL
Intervention: White Noise
Number of subjects: 9
Study 32838628 — intervention group
Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 9
Study 32219761 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid arm, receiving two 330 mg omega-3 fatty acid capsules daily and placebo (for vitamin D3) weekly
Number of subjects: 0
Study 32219761 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D arm, receiving a 50,000 IU vitamin D3 soft gel weekly and two placebos (for omega-3 fatty acids) daily
Number of subjects: 0
Study 32219761 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-supplementation arm, receiving a 50,000 IU vitamin D3 soft gel weekly and two 330 mg omega-3 fatty acids capsules daily for 8 weeks
Number of subjects: 0
Study 32219761 — intervention group
Group type: COMPARATOR
Intervention: Controls, receiving placebos
Number of subjects: 0